Innoviva (INVA) Cash from Investing Activities Growth (5y) (2015 - 2026)

Innoviva (INVA) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Innoviva 1.58 Bn 979.49 Mn 75.83 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 27.75%
Sep 30, 2025 31.84%
Jun 30, 2025 46.43%
Mar 31, 2025 -33.00%
Sep 30, 2024 -24.83%
Mar 31, 2024 10.31%
Sep 30, 2023 -45.66%
Mar 31, 2023 -27.33%
Sep 30, 2022 -17.11%
Jun 30, 2022 -26.56%
Mar 31, 2022 -53.03%
Sep 30, 2021 44.11%
Jun 30, 2021 41.51%
Mar 31, 2021 -33.61%
Dec 31, 2020 -38.94%
Sep 30, 2020 29.23%
Jun 30, 2020 -17.14%
Mar 31, 2020 -26.28%
Dec 31, 2019 52.25%
Sep 30, 2019 23.17%